These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 29788955)

  • 1. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.
    Matsutani D; Sakamoto M; Kayama Y; Takeda N; Horiuchi R; Utsunomiya K
    Cardiovasc Diabetol; 2018 May; 17(1):73. PubMed ID: 29788955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
    Kusunose K; Imai T; Tanaka A; Dohi K; Shiina K; Yamada T; Kida K; Eguchi K; Teragawa H; Takeishi Y; Ohte N; Yamada H; Sata M; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):186. PubMed ID: 34521417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of glycemic control on aortic stiffness, left ventricular mass and diastolic longitudinal function in type 2 diabetes mellitus.
    Kozakova M; Morizzo C; Fraser AG; Palombo C
    Cardiovasc Diabetol; 2017 Jun; 16(1):78. PubMed ID: 28623932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
    Yamada H; Tanaka A; Kusunose K; Amano R; Matsuhisa M; Daida H; Ito M; Tsutsui H; Nanasato M; Kamiya H; Bando YK; Odawara M; Yoshida H; Murohara T; Sata M; Node K;
    Cardiovasc Diabetol; 2017 May; 16(1):63. PubMed ID: 28490337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
    Oka S; Kai T; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
    BMC Cardiovasc Disord; 2021 Apr; 21(1):217. PubMed ID: 33926386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of glycemic variability with left ventricular diastolic function in type 2 diabetes mellitus.
    Yokota S; Tanaka H; Mochizuki Y; Soga F; Yamashita K; Tanaka Y; Shono A; Suzuki M; Sumimoto K; Mukai J; Suto M; Takada H; Matsumoto K; Hirota Y; Ogawa W; Hirata KI
    Cardiovasc Diabetol; 2019 Dec; 18(1):166. PubMed ID: 31805945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Improved Glycemic Control on Cardiac Function in Type 2 Diabetes Mellitus.
    Leung M; Wong VW; Hudson M; Leung DY
    Circ Cardiovasc Imaging; 2016 Mar; 9(3):e003643. PubMed ID: 26962125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
    Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design.
    Imazu M; Nakano A; Ito S; Hamasaki T; Kitakaze M;
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):363-370. PubMed ID: 30850916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
    Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus.
    Liu JH; Chen Y; Yuen M; Zhen Z; Chan CW; Lam KS; Tse HF; Yiu KH
    Cardiovasc Diabetol; 2016 Feb; 15():22. PubMed ID: 26842466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.
    Zhang DP; Xu L; Wang LF; Wang HJ; Jiang F
    Cardiovasc Diabetol; 2020 Jan; 19(1):10. PubMed ID: 31969144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes.
    Sezai A; Sekino H; Unosawa S; Taoka M; Osaka S; Tanaka M
    Cardiovasc Diabetol; 2019 Jun; 18(1):76. PubMed ID: 31167663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
    Bizino MB; Jazet IM; Westenberg JJM; van Eyk HJ; Paiman EHM; Smit JWA; Lamb HJ
    Cardiovasc Diabetol; 2019 Apr; 18(1):55. PubMed ID: 31039778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
    Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
    Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative evaluation of subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus by three-dimensional echocardiography.
    Chen X; Guo H; Yang Q; Fang J; Kang X
    Int J Cardiovasc Imaging; 2020 Jul; 36(7):1311-1319. PubMed ID: 32277320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross-sectional comparison with non-diabetic weight-matched controls.
    Ofstad AP; Urheim S; Dalen H; Orvik E; Birkeland KI; Gullestad L; W Fagerland M; Johansen OE; Aakhus S
    J Diabetes; 2015 Nov; 7(6):779-90. PubMed ID: 25350248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population.
    Giorda CB; Cioffi G; Lucci D; Nada E; Ognibeni F; Mancusi C; Latini R; Maggioni AP;
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):547-555. PubMed ID: 31418140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissipative energy loss within the left ventricle detected by vector flow mapping in diabetic patients with controlled and uncontrolled blood glucose levels.
    Li CM; Bai WJ; Liu YT; Tang H; Rao L
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1151-1158. PubMed ID: 28299608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.